We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+43.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.56B
AUM Growth
+$116M
(+3.4%)
Cap. Flow
-$205M
Cap. Flow
% of AUM
-5.76%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
127
New
13
Increased
20
Reduced
25
Closed
31
Avg Time Held Equity + Options
8.4
quarters
Top 10 Avg Time Held Equity + Options
5.8
quarters
Top 20 Avg Time Held Equity + Options
6.1
quarters
Avg Time Held Equity only
8.6
quarters
Top 10 Avg Time Held Equity only
5.8
quarters
Top 20 Avg Time Held Equity only
6.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$79.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$45.9M |
| 3 |
Vaxcyte
PCVX
|
+$45.9M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$39.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
+$38.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$158M |
| 2 |
Relmada Therapeutics
RLMD
|
+$88.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$43.3M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$38.4M |
| 5 |
Edwards Lifesciences
EW
|
+$27.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Miscellaneous | 2.57% |
| 3 | Financials | 0.08% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Verrica Pharmaceuticals
VRCA
$64.8M
| $13.9M | 0.39% |
503,898
| – | – |
2018 Q2
18 quarters
|
|
52
Axogen
AXGN
$2.13B
| $13.9M | 0.39% |
1,388,126
+438,500
| +46% | +$4.87M |
2022 Q3
1 quarter
|
|
53
DELISTED
Revance Therapeutics, Inc.
RVNC
| $13.5M | 0.38% |
729,097
-79,574
| -10% | -$1.82M |
2022 Q1
3 quarters
|
|
54
Cytek Biosciences
CTKB
$699M
| $13.2M | 0.37% |
1,289,534
| – | – |
2022 Q3
1 quarter
|
|
55
Artivion
AORT
$1.05B
| $13.2M | 0.37% |
1,085,860
-118,369
| -10% | -$1.42M |
2021 Q4
4 quarters
|
|
56
BridgeBio Pharma
BBIO
$12.5B
| $12.9M | 0.36% |
1,697,033
| – | – |
2019 Q2
14 quarters
|
|
|
ISEE
57
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $12.6M | 0.35% |
587,400
-446,769
| -43% | -$9.54M |
2019 Q4
12 quarters
|
|
58
Neurocrine Biosciences
NBIX
$13.8B
| $11.9M | 0.34% |
100,050
| – | – |
2013 Q2
38 quarters
|
|
59
Larimar Therapeutics
LRMR
$220M
| $11.8M | 0.33% |
2,860,000
| – | – |
2022 Q3
1 quarter
|
|
60
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $11.4M | 0.32% |
104,307
-8,858
| -8% | -$1.32M |
2020 Q4
8 quarters
|
|
61
Intuitive Surgical
ISRG
$147B
| $10.6M | 0.3% |
+40,000
| New | +$9.75M |
2022 Q4
0 quarters
|
|
62
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $9.72M | 0.27% |
363,197
| – | – |
2019 Q2
14 quarters
|
|
63
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $9.15M | 0.26% |
293,362
-394,062
| -57% | -$12.9M |
2021 Q4
4 quarters
|
|
64
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $7.43M | 0.21% |
1,486,992
| – | – |
2021 Q1
7 quarters
|
|
65
DELISTED
scPharmaceuticals
SCPH
| $6.83M | 0.19% |
+952,380
| New | +$5.82M |
2022 Q4
0 quarters
|
|
66
DELISTED
HilleVax
HLVX
| $6.79M | 0.19% |
406,024
-358,883
| -47% | -$6.48M |
2022 Q2
2 quarters
|
|
67
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $6.6M | 0.19% |
109,409
-8,467
| -7% | -$567K |
2021 Q2
6 quarters
|
|
|
ISO
68
DELISTED
IsoPlexis Corporation Common Stock
ISO
| $6.35M | 0.18% |
4,095,498
| – | – |
2021 Q4
4 quarters
|
|
69
Penumbra
PEN
$12.6B
| $5.65M | 0.16% |
+25,400
| New | +$4.97M |
2022 Q4
0 quarters
|
|
70
Aclaris Therapeutics
ACRS
$498M
| $5.37M | 0.15% |
341,239
| – | – |
2021 Q1
7 quarters
|
|
71
Natera
NTRA
$57.7B
| $5.22M | 0.15% |
130,000
+10,000
| +8% | +$412K |
2022 Q3
1 quarter
|
|
72
DELISTED
Cymabay Therapeutics
CBAY
| $4.45M | 0.12% |
+708,993
| New | +$2.69M |
2022 Q4
0 quarters
|
|
73
PUT
Filana Therapeutics
FLNA
$35.3M
| $4.43M | 0.12% |
+150,000
| New | +$5.39M |
2022 Q4
0 quarters
|
|
74
enVVeno Medical
NVNO
$5.38M
| $3.99M | 0.11% |
22,332
| – | – |
2021 Q4
4 quarters
|
|
75
Nanobiotix
NBTX
$1.08B
| $3.89M | 0.11% |
1,059,800
| – | – |
2020 Q4
8 quarters
|
|
Similar funds
QP
RWM
AWA
WHRC
KGA
LSERS
CAG
MCM
Perceptive Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, Perceptive Advisors held 127 positions worth $3.56B, up 3.4% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Perceptive Advisors withdrew a net $205M in Q4 2022, closing 31 positions and reducing 25 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $109M.
- Perceptive Advisors's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 960,000 shares worth $109M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q4 2022, an estimated $45.9M increase.
- Perceptive Advisors's biggest Q4 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $38.4M.
- Perceptive Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $158M.
- Perceptive Advisors's ten largest holdings make up 46% of its $3.56B portfolio in Q4 2022.
- Perceptive Advisors opened 13 new positions and closed 31 in Q4 2022.
- Perceptive Advisors's portfolio value rose 3.4% quarter-over-quarter to $3.56B.
Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.